US Pharma MarketingMerck weighs use of COVID antiviral Lagevrio as Ebola outbreak worsens: report
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for COVID-19 under an emergency use authorization during the pandemic. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing…
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for COVID-19 under an emergency use authorization during the pandemic.
Source: FiercePharma